Moderna (MRNA) and the University of Oxford have received authorization from the UK Medicines and Healthcare products Regulatory Agency to begin a phase 1/2 study of mRNA-4194, an investigational cancer vaccine for people with lynch syndrome, according to a Monday statement.
Lynch syndrome is an inherited condition that results in high predisposition to cancer.
The study, funded by Moderna, will be run by the Oxford's Oncology Clinical Trials Office and its cancer center, the organizations said.
A second phase will increase enrollment to multiple UK locations and is expected to begin in 2027, the organizations said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments